Myriad Launches FirstGene for Earlier Prenatal Genetic Screening
SALT LAKE CITY, Utah, July 21, 2026 Myriad Genetics has officially launched the FirstGene® Multiple Prenatal Screen, introducing what...
Myriad Genetics
Advertisement
Myriad Genetics Prolaris Study Validates Prostate Risk Test
SALT LAKE CITY, July 2, 2026 Myriad Genetics, Inc. announced the publication of the largest individual-patient-data meta-analysis evaluating its...
Myriad Launches Prolaris + AI for Prostate Cancer
SALT LAKE CITY, May 26, 2026 Myriad Genetics announced the launch of Prolaris® + AI, the first prostate cancer...
Myriad CDx Test Approved to Guide Ovarian Cancer Therapy
SALT LAKE CITY, March 17, 2026 Myriad Genetics, Inc. announced that the U.S. Food and Drug Administration (FDA) has...
Myriad Genetics Advances Precision Medicine at Q4 2025 Forums
Dateline — SALT LAKE CITY, November 11, 2025:Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in molecular diagnostic testing...
Advertisement
